Literature DB >> 23996939

Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report.

Alon B Neidich1, Eitan M Neidich, Andy Lee, Julie Nicoletta, Richard J Rohrer, Lawrence S Milner, Jeffrey T Cooper.   

Abstract

A white girl presented at 8 months of age with thrombotic microangiopathy, followed by recurrent episodes of renal dysfunction, hemolysis, and thrombocytopenia, compatible with atypical hemolytic uremic syndrome. The episodes of the syndrome were treated by a combination of infusions of fresh frozen plasma, plasmapheresis, and continuous venovenous hemodialysis. Interval resolution occurred between episodes. At 2 years of age, prophylactic infusions of fresh frozen plasma were started between relapses, but this proved to be poorly protective; however, introduction of prophylactic intravenous gamma globulin at age 3.5 years resulted in prolonged remission (42 months). Serum levels of the third and fourth components of complement, total hemolytic complement, and complement factor H were normal. Results of the third component functional assay were low before and normalized after the start of immunoglobulin G prophylaxis. A missense mutation of complement factor H was identified. At 6 years of age, the patient underwent bilateral native nephrectomy and started long-term peritoneal dialysis, followed by a combined liver-kidney transplant at age 8 years. Four and a half years after transplant, she has excellent renal and liver graft function without recurrence of atypical hemolytic uremic syndrome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996939     DOI: 10.7182/pit2013151

Source DB:  PubMed          Journal:  Prog Transplant        ISSN: 1526-9248            Impact factor:   1.187


  1 in total

1.  Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?

Authors:  Jeffrey Saland
Journal:  Pediatr Nephrol       Date:  2013-12-22       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.